@article { author = {Nhokaew, Wilasinee and Kleebkaow, Pilaiwan and Chaisuriya, Nipon and Kietpeerakool, Chumnan}, title = {Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {20}, number = {4}, pages = {1161-1169}, year = {2019}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {10.31557/APJCP.2019.20.4.1161}, abstract = {Objective: To examine the expression of programmed death ligand 1 (PD-L1) in type I and type II epithelialovarian cancers (EOC) and its associations with outcomes. Methods: Records of 132 women with EOC were reviewed.Immunostaining of PD-L1 was performed with formalin-fixed, paraffin-embedded specimens. Expression of PD-L1 wasclassified into four categories (0; 1+; 2+; 3+) according to intensity of expression. Expression of PD-L1 ≥2+ was deemedto be high. Results: Of the 132 women, 75 (56.8%) and 57 (43.2%) women had type I and type II tumors, respectively.Approximately 70% of cases exhibited high PD-L1 expression. There was no significant difference in the rate of highPD-L1 expression between the two EOC types (65.3% versus 59.6%). In type I tumors, high PD-L1 expression wasassociated with more advanced stages (51.0% versus 34.6%), greater recurrence (46.9% versus 26.9%), and shortermedian progression-free survival (27 months versus 62 months) than low expression. In type II tumors, there were noapparent differences between high and low expression of PD-L1 in terms of the percentage of advanced-stage tumors(82.6% versus 79.4%), recurrence (56.5% versus 58.8%), and median progression-free survival (21 months versus24 months). Conclusion: high PD-L1 expression is associated with worse oncological outcomes in type I EOC. Thisfinding emphasizes the merit of further studies to confirm this promising result and to determine the potential role ofPD-L1 blockade therapy in type I EOC.}, keywords = {Ovarian Cancer,prognostic value,survival,PD-L1 expression,Immunotherapy}, url = {https://journal.waocp.org/article_85866.html}, eprint = {https://journal.waocp.org/article_85866_2b34f06a9d116d8babfe862b516a8333.pdf} }